

RESEARCH

Open Access



The impact of body weight on the development of peritoneal metastases in colorectal cancer patients: results from a nationwide cohort study

Vincent C. J. van de Vlasakker¹, Felice N. van Erning^{1,2}, Robin J. Lurvink^{1,2}, Ignace H. J. T. de Hingh^{1,2,3} and Simon W. Nienhuijs^{1*}

Abstract

Background Obesity is a major global health problem and an important risk factor for colorectal cancer (CRC) is increased body weight. Obesity plays a role in the peritoneal dissemination of cancer; however, it is unclear whether this also applies for peritoneal dissemination of CRC. The purpose of this study was to provide insight in the role of obesity on the peritoneal dissemination of colorectal cancer.

Methods Of all patients diagnosed with CRC in the Netherlands in the first half of 2015, follow-up data was completed in 2019. Weight at time of primary diagnosis was categorized as underweight, normal weight, overweight, or obese. Logistic regression modelling was used to assess the association between weight and the presence of synchronous colorectal peritoneal metastases (CPM), and Cox regression modelling was used to assess the association between weight and metachronous CPM. Patient and tumor characteristics were taken into account. The analyses were adjusted for tumor stage, nodal stage, tumor location, and tumor histology.

Results In total, 6436 patients were included in this study. Two-hundred ninety-three (4.6%) patients presented with synchronous CPM at the time of primary diagnosis, while another 278 (5.1%) patients developed metachronous CPM after a median time of 16.5 months. Univariable and multivariable logistic regression modelling did not identify an effect of weight on the presence of synchronous CPM. Neither underweight (odds ratio [OR] 1.10, 95% CI 0.48–2.54), nor overweight (OR 0.96, 95% CI 0.71–1.29), or obesity (OR 0.84, 95% CI 0.56–1.26) was either positively or negatively associated with the presence of synchronous peritoneal metastases as compared to normal weight. Univariable and multivariable Cox regression modelling did not identify an effect of weight on the development of metachronous CPM. Neither underweight (HR 0.162, 95% CI 0.02–1.16), nor overweight (HR 1.07, 95% CI 0.82–1.39), or obesity (HR 1.02, 95% CI 0.73–1.16) was either positively or negatively associated with the presence of synchronous peritoneal metastases as compared to normal weight.

Conclusion CRC patients who are overweight or obese are not more at risk for the presence of synchronous CPM nor development of metachronous CPM than their normal-weight counterparts.

*Correspondence:

Simon W. Nienhuijs
simon.nienhuijs@cze.nl

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Keywords Colorectal neoplasms, Peritoneal metastases, Body mass index (BMI), Weight, Colorectal cancer, Risk factors

Background

Colorectal cancer (CRC) constitutes a major global health burden, with nearly two million new cases every year [1]. In the Netherlands alone, there were over 11,000 newly diagnosed CRC patients in 2020 [2]. CRC disseminates often, and approximately 20% of newly diagnosed patients present with metastasized disease [2]. The peritoneum is the second most affected organ after the liver, with 5.7% of newly diagnosed CRC patients presenting with synchronous colorectal peritoneal metastases (CPM) [3].

This relatively large portion of CRC patients presenting with PM might in part be explained by the lack of clinical symptoms in early-stage CRC [3]. Obese patients in particular are at risk for underappreciation of symptoms, as many symptoms of advanced stage CRC, such as irregularity of bowel movements, can be caused by obesity itself [4, 5].

The role of obesity in CRC might be more extensive than just underappreciation of symptoms, as obesity is widely recognized to be a risk factor for the development of many types of cancer, amongst which CRC [6]. Moreover, obesity was shown to be a driver of the dissemination of cancer through the secretion of adipokines and pro-inflammatory cytokines [7]. Intra-abdominal cancers have a predilection to metastasize to peritoneal locations that are rich in adipocytes, as these adipocytes provide energy for tumor growth [8, 9]. Since obesity is associated with an increase in adipocyte size, it might be deduced that obese individuals have more energy available for tumor growth and are therefore more at risk for peritoneal metastases. However, whether this hypothesis for the role of obesity in peritoneal dissemination holds true for colorectal cancer remains to be elucidated.

Almost 40% of the worldwide population is currently overweight, and an additional 13% is living with obesity [1]. With an expected increase in these numbers, and the high prevalence of CRC and CPM worldwide, the role of obesity in the development and progression of CPM deserves to be investigated. The present population-based study aimed to provide insight into the effect of obesity on peritoneal dissemination of CRC.

Methods

Data source

Data from the Netherlands Cancer Registry (NCR) were used for this nationwide population-based cohort study.

In this registry, all newly diagnosed malignancies in the Netherlands are registered by trained data managers who routinely extract data on patient, tumor, and treatment characteristics from hospital records. All patients diagnosed with CRC between January 1, 2015, and June 30, 2015, in the Netherlands were evaluated. In 2019, data managers from the NCR extracted follow-up data regarding local and systemic recurrences and their treatment from hospital records for all patients, while data on vital status were obtained through annual linkage to the municipal administrative database. Since all data were anonymized, no medical ethical approval was required for this study. The study was conducted in accordance with the Declaration of Helsinki and was approved by the scientific research board of the Netherlands Cancer Registry.

Patient, tumor, and treatment characteristics

The anatomical sites of both primary tumors as well as of metastases were registered according to the International Classification of Disease-Oncology (ICD-O). Staging of disease was done according to the seventh edition of the tumor node metastasis (TNM) classification. Preferably, the pathological TNM (pTNM) stadium was used in the present study. If pTNM stadium was not available, clinical TNM (cTNM) stadium was used. Similarly, if patients were diagnosed with multiple primary tumors, the primary tumor that was initially diagnosed was used in the analyses. If the initial diagnosis of multiple primary tumors occurred simultaneously, the primary tumor with the highest TNM stage was included in the analyses.

The primary tumor location was categorized into three anatomical subsites according to the corresponding ICD-0 codes: (1) right-sided colon (C18.0, C18.2–18.4: cecum, ascending colon, hepatic flexure, transverse colon), (2) left-sided colon (C18.5–18.7: splenic flexure, descending colon, sigmoid), and (3) rectum (C19.9–20.9: rectosigmoid and rectum). Patients with a different primary tumor location (e.g., [Appendix](#)) were excluded.

The histology of the primary tumor was categorized into three histological subtypes: (1) adenocarcinoma (8000, 8010, 8020, 8140, 8144, 8210, 8211, 8220, 8255, 8261, 8262, 8263 and 8560), (2) mucinous adenocarcinoma (8480, 8481), and (3) signet ring carcinoma (8490). Patients with a different primary tumor histology (e.g., neuroendocrine tumor) were excluded.

Metastases were defined as peritoneal metastases (C16.0–16.9, C17.0–C17.9, C18.0–C18.9, C19.9, C20.9,

C21.8, C23.9, C26.9, C48.0–C48.8, C49.4–C 49.5, C52.9, C53.9, C54.0–C54.9, C55.9, C56.9–C57.8, C66.9–C67.9, and C76.2) or as systemic metastases (any other metastatic location).

Metastases were defined in the NCR database as synchronous metastases if diagnosed <90 days after diagnosis of the primary tumor and were defined as metachronous metastases if diagnosed \geq 90 days after diagnosis of the primary tumor.

Curative treatment was defined as surgical treatment of primary CRC. Only patients without synchronous peritoneal metastases who underwent curative treatment were included in the subsequent analyses (i.e., identifying risk factors for the development of metachronous peritoneal metastases).

Weight and length, established at the time of the primary diagnosis, were used to calculate body mass index (BMI) in kg/m^2 , which was subsequently categorized into four categories: (1) underweight ($\text{BMI} < 18.5$), (2) normal weight ($18.5 \leq \text{BMI} < 25$), (3) overweight ($25 \leq \text{BMI} < 30$), and (4) obesity ($\text{BMI} \geq 30$).

Statistical analyses

Baseline characteristics were compared between patients amongst the four weight categories. Differences in continuous variables between patients amongst the four weight categories were compared using ANOVA tests and presented as mean \pm standard deviation. Differences in categorical variables between patients amongst the four weight categories were compared using χ^2 tests and presented as n (%). Missing data were excluded from the comparative analyses.

A multivariable binary logistic regression model was used to assess the association between weight and the presence of synchronous PM. The model was adjusted for patient and tumor characteristics with a p -value < 0.10 in univariable analyses.

A multivariable Cox regression model was used to assess the association between weight and the development of metachronous PM. The model was adjusted for patient and tumor characteristics with a p -value < 0.10 in univariable analyses. In order to prevent overfitting of the multivariable models, the number of variables was limited to ensure a minimum of 10 events per degree of freedom. Testing of multicollinearity was performed for each of the variables within the model. If a collinearity tolerance of <0.25 occurred, or if a variance inflation factor (VIF) of >3.0 occurred, corrections of the model would be performed. All tests were performed in a two-sided fashion, and a p -value of 0.05 was considered to be the upper limit for overall type 1 error, and thus, $p < 0.05$ indicated statistical significance. Statistical analyses were

performed using SPSS, version 26.0 (IBM corporation Armonk, NY, USA).

Results

The final study population was comprised of 6436 patients (Fig. 1). In total, 293 (4.6%) patients were diagnosed with synchronous peritoneal metastases, of whom 108 were diagnosed as solitary PM and 185 as both synchronous peritoneal and systemic metastases. A total of 6143 patients were diagnosed without synchronous peritoneal metastases, and 88.5% ($n = 5434$) of them underwent curative treatment. Of this latter group, 278 (5.1%) patients were diagnosed with metachronous peritoneal metastases after a median time of 16.5 months (*IQR* 11.0–24.1).

Table 1 contains a detailed comparison of baseline characteristics between patients distributed over the weight categories. Patients with underweight ($\text{BMI} < 20 \text{ kg}/\text{m}^2$) were more often female, were more often diagnosed with a right-sided colon tumor, and diagnosed with synchronous peritoneal and systemic metastases in comparison to others (Table 1). Patients with obesity ($\text{BMI} > 30 \text{ kg}/\text{m}^2$) were more often men and were less often diagnosed with synchronous metastases (Table 1).

The presence and development of peritoneal metastases

Synchronous peritoneal metastases were diagnosed in 4.9% of CRC patients (Table 1).

Amongst patients without synchronous peritoneal metastases, who underwent curative treatment ($n = 5434$), 278 patients (5.1%) were diagnosed with metachronous peritoneal metastases after a median time of 16.5 months (*IQR*: 11.0–24.1 months). The 1- and 3-year cumulative incidence of metachronous peritoneal metastases were 1.8% and 5.0%, respectively.

Patients with normal weight and patients with overweight were comparable in regard to the diagnosis frequency of synchronous and metachronous PM (normal weight: 5.5% vs 5.0%, respectively; overweight 4.1% vs 5.2%, respectively).

The association between weight and the presence of synchronous peritoneal metastases

Univariable logistic regression analyses are presented in Table 4 in the Appendix. Multivariable logistic regression analyses (Nagelkerke $R^2 = 0.352$) are presented in Table 2. Neither underweight (*OR* 1.10, 95% *CI* 0.48–2.54), nor overweight (*OR* 0.96, 95% *CI* 0.71–1.29), or obesity (*OR* 0.84, 95% *CI* 0.56–1.26) was either positively or negatively associated with the presence of synchronous peritoneal metastases as compared to normal weight. Variables positively associated with the presence of synchronous peritoneal metastases were tumor stage, nodal stage, tumor




Fig. 1 Flowchart of the study population with the incidence and onset of colorectal peritoneal metastases and systemic metastases

histology, and the presence of synchronous systemic metastases (Table 2). The rectum as primary tumor location was found to be negatively associated with the presence of synchronous peritoneal metastases (Table 2). No violations of the multicollinearity assumptions occurred.

The association between weight and the development of metachronous peritoneal metastases

Univariable Cox regression analyses are presented in Table 5 in the Appendix. Multivariable Cox regression analyses are presented in Table 3. Neither underweight (HR 0.162, 95% CI 0.02–1.16), nor overweight (HR 1.07, 95% CI 0.82–1.39), or obesity (HR 1.02, 95% CI 0.73–1.16) was either positively or negatively associated with the development of metachronous peritoneal metastases

as compared to normal weight (Table 3). Patients who were diagnosed with a mucinous adenocarcinomas or signet ring cell tumors were more likely to develop metachronous PM. Other variables positively associated with the development of metachronous peritoneal metastases were a more advanced tumor stage (i.e., T3 or T4 tumor stage), a more advanced nodal stage (i.e., N1 or N2 nodal stage), and the presence of synchronous systemic metastases (Table 2). No violations of the multicollinearity assumptions occurred.

Discussion

The present study found that weight was not associated with the presence of synchronous colorectal peritoneal metastases, nor was it associated with the development

Table 1 Baseline characteristics of all patients per weight category

	BMI < 18.5 (n = 121) (2%)	BMI 18.5–24.9 (n = 2448) (38%)	BMI 25–29.9 (n = 2633) (41%)	BMI > 30 (n = 1234) (19%)	p-value*
Age (years), mean (SD)	68.9 ± 11.5	68.5 ± 11.0	68.4 ± 9.7	67.5 ± 8.8	0.012
Sex, n (%)					< 0.001
Male	34 (28.1)	1323 (54.0)	1709 (64.9)	682 (55.3)	
Female	87 (71.9)	1125 (46.0)	924 (35.1)	552 (44.7)	
Tumor location, n (%)					< 0.001
Right colon	51 (43.6)	770 (31.8)	779 (29.8)	377 (30.7)	
Left colon	32 (27.4)	845 (34.9)	942 (36.1)	507 (41.3)	
Rectum	34 (29.1)	805 (33.3)	891 (34.1)	344 (28.0)	
Tumor differentiation, n (%)					< 0.001
Good/moderate	77 (63.6)	1781 (72.8)	2058 (78.2)	968 (78.4)	
Poor/undifferentiated	15 (12.4)	225 (9.2)	210 (8.0)	107 (8.7)	
Missing	29 (24.0)	442 (18.1)	365 (13.9)	159 (12.9)	
Tumor histology					0.910
Adenocarcinoma	110 (90.9)	2238 (91.4)	2404 (91.3)	1113 (90.2)	
Mucinous adenocarcinoma	9 (7.4)	184 (7.5)	201 (7.6)	105 (8.5)	
Signet ring cell carcinoma	2 (1.7)	26 (1.1)	28 (1.1)	16 (1.3)	
Synchronous PM, n (%)					0.005
Yes	9 (7.4)	135 (5.5)	108 (4.1)	41 (3.3)	
No	112 (92.6)	2313 (94.5)	2525 (95.9)	1193 (96.7)	
Synchronous systemic metastases, n (%)					< 0.001
Yes	30 (24.8)	517 (21.1)	415 (15.8)	150 (12.2)	
No	91 (75.2)	1931 (78.9)	2218 (84.2)	1084 (87.8)	
Tumor stage, n (%)					< 0.001
T0–2	17 (15.3)	699 (30.2)	929 (35.3)	458 (37.1)	
T3	70 (63.1)	1191 (51.4)	1278 (48.5)	600 (48.6)	
T4	24 (21.6)	425 (17.4)	327 (12.4)	139 (11.3)	
Missing data	10 (8.3)	133 (5.4)	99 (3.8)	37 (3.0)	
Nodal stage, n (%)					0.238
N0	53 (43.8)	1019 (41.6)	1155 (43.9)	560 (45.4)	
N1	39 (32.2)	826 (33.7)	861 (32.7)	400 (32.4)	
N2	20 (16.5)	521 (21.3)	512 (19.4)	228 (18.5)	
Missing data	9 (7.4)	82 (3.3)	105 (4.0)	46 (3.7)	

BMI Body mass index (in kg/m²), n Number, SD Standard deviation, PM Peritoneal metastases

* Missing data were excluded from the comparative analyses

of metachronous colorectal peritoneal metastases. This is an interesting finding, since previous research has shown that 11% of all primary colorectal cancer (CRC) cases in Europe can be attributed to an increased weight status (i.e. a BMI within the overweight or obese categories) [10].

Intra-abdominal cancers, such as colorectal cancer, have a preference to disseminate to the omentum, a peritoneal organ that consists largely of adipocytes, suggesting a role of adipocytes in the dissemination of cancer [11]. Mouse models of ovarian cancer have shown that omental adipocytes promote migration and invasion of

ovarian cancer cells, and that ovarian cancer cells utilize the readily available fatty acids as a source for growth [8]. Obesity promotes peritoneal dissemination of ovarian cancer, as adipocytes and fatty acids are more abundantly present in the abdomen of obese individuals [9]. Moreover, obesity stimulates the secretion of adipokines and pro-inflammatory cytokines, thus priming the peritoneal tumor environment further for metastasis growth [9].

We hypothesized that in CRC, similar effects might occur and thus expected a higher incidence of synchronous and metachronous peritoneal metastases in patients who were overweight or obese. However, in this

Table 2 Multivariable logistic regression analyses for the presence of synchronous peritoneal metastases

Variable	Crude rate synchronous PM n (%)	Multivariable logistic regression analysis		
		OR	95% CI	p-value*
Weight category				
1. (BMI < 18.5); underweight	9 (7.4)	1.099	0.477–2.535	0.824
2. (BMI 18.5–25); normal weight	135 (5.5)	Ref	Ref	Ref
3. (BMI 25–30); overweight	108 (4.1)	0.955	0.707–1.288	0.761
4. (BMI ≥ 30); obesity	41 (3.3)	0.840	0.558–1.263	0.401
Primary tumor location				
Right colon	137 (6.9)	1.02	0.759–1.368	0.898
Left colon	116 (5.0)	Ref	Ref	Ref
Rectum	26 (1.3)	0.291	0.182–0.464	<0.001
Tumor differentiation				
Good/moderate	124 (2.5)	Ref	Ref	Ref
Poor/undifferentiated	49 (8.8)	1.223	0.814–1.838	0.332
Tumor stage				
T0–2	6 (0.3)	Ref	Ref	Ref
T3	68 (2.2)	4.203	1.780–9.901	0.001
T4	146 (16.0)	19.821	8.408–46.72	<0.001
Nodal stage				
N0	55 (2.0)	Ref	Ref	Ref
N1	75 (3.5)	1.185	0.796–1.765	0.402
N2	120 (9.4)	2.145	1.433–3.212	<0.001
Tumor histology				
Adenocarcinoma	224 (3.8)	Ref	Ref	Ref
Mucinous adenocarcinoma	48 (9.6)	2.337	1.525–3.579	<0.001
Signet ring cell carcinoma	21 (29.2)	4.930	2.481–9.796	<0.001
Synchronous systemic metastasis				
No	108 (2.0)	Ref	Ref	Ref
Yes	185 (16.6)	4.726	3.432–6.508	<0.001

PM Peritoneal metastases, n Number, OR Odds ratio, CI Confidence interval, BMI Body mass index (in kg/m²)

* Missing data were excluded from the regression model

prospective nationwide cohort, no effect of weight on the presence of synchronous peritoneal metastases, nor on the development of metachronous peritoneal metastases, was observed. This suggests that, unlike ovarian cancer cells, colorectal cancer cells might be relatively insensitive to obesity-related priming of the microenvironment and dissemination thereto.

However, the absence of a relationship between increased weight and the presence of synchronous CPM or development of metachronous CPM might in part reflect the limitations of weight as an approximation of metabolic health. The dysfunctional and pro-inflammatory processes that promote cancer and that are often attributed to obesity are a result of unhealthy metabolic processes, rather than of weight itself [9, 12]. This could have attenuated the results of the present study, as no distinction could be made between metabolically healthy

obese individuals and metabolically unhealthy normal weight individuals. Indeed, in a previous study that investigated the role of obesity on the development of peritoneal metastases, it was reported that increased BMI has a protective effect on peritoneal seeding. Simultaneously, it was reported that increased visceral adipose tissue ratios, a more adequate approximation for metabolic health, exerted a hazardous effect [13]. Their contradictory findings emphasize the limitations of the use of weight in research.

In addition to weight being an imperfect approximation of metabolic health, other limitations to the present study were caused by the nature of these nationwide data and might have contributed to the rejection of our research hypothesis. The NCR only registers a certain set of variables, which does not include the peritoneal cancer index (PCI) score. If

Table 3 Multivariable Cox regression analyses for the development of metachronous peritoneal metastases after curative primary tumor resection

Variable	Crude rate metachronous PM after median FU of 16.5 months n (%)	Multivariable Cox regression analysis*		
		HR	95% CI	p-value
Weight category				
1. (BMI < 18.5); underweight	1 (1.1)	0.162	0.023–1.159	0.125
2. (BMI 18.5–25); normal weight	107 (5.4)	Ref	Ref	Ref
3. (BMI 25–30); overweight	117 (5.2)	1.065	0.819–1.386	0.638
4. (BMI ≥ 30); obesity	53 (4.8)	1.017	0.730–1.159	0.919
Tumor differentiation				
Good/moderate	206 (4.7)	Ref	Ref	Ref
Poor/undifferentiated	38 (8.7)	1.232	0.862–1.761	0.252
Tumor stage				
T0–2	20 (1.0)	Ref	Ref	Ref
T3	152 (5.5)	4.003	2.456–6.525	<0.001
T4	106 (17.0)	11.447	6.844–19.14	<0.001
Nodal stage				
N0	51 (2.0)	Ref	Ref	Ref
N1	118 (6.5)	2.038	1.456–2.852	<0.001
N2	107 (11.0)	2.836	1.898–4.045	<0.001
Tumor histology				
Adenocarcinoma	233 (4.7)	Ref	Ref	Ref
Mucinous adenocarcinoma	34 (8.2)	1.979	1.313–2.983	0.001
Signet ring cell carcinoma	11 (24.4)	4.455	2.247–8.831	<0.001
Synchronous systemic metastasis				
Yes	68 (15.9)	3.045	2.279–4.068	<0.001
No	210 (4.2)	Ref	Ref	Ref

PM Peritoneal metastases, n Number, HR Hazard ratio, CI Confidence interval, BMI Body mass index (in kg/m²)

* Missing data were excluded from the regression model

obesity would induce intra-abdominal cancer growth, rather than its dissemination, this could have resulted in a higher PCI score in individuals who were obese. However, this could not be assessed due to limitations of the data, and future research and registries should focus on this issue. Additionally, despite being a nationwide cohort, the number of patients with peritoneal metastases was limited, thereby restricting the power of the study and thus decreasing the likelihood of accepting our research hypothesis. Furthermore, due to the timing of the baseline measurements (at the time of the primary cancer diagnosis), weight, and thus BMI, might have been affected by the cancer even prior to the diagnosis. Thereby, patients who experienced cancer-associated weight loss might have been categorized into a lower BMI category. Lastly, due to the retrospective nature of the data, it was unknown whether patients had undergone true curative surgery for their primary tumor and their synchronous systemic

metastases or merely a palliative resection of the primary tumor. As some of these patients might not have been cured, they could have had a higher rate of developing peritoneal metastases, thereby causing an overestimation of the incidence of metachronous peritoneal metastases. Further research is needed to resolve and overcome these limitations and to provide robust evidence on this topic.

Conclusion

This study found no relationship between increased weight and the presence of synchronous CPM, nor between increased weight and the development of metachronous CPM. Thus, CRC patients with overweight and obesity are not at a higher risk for CPM, despite possibly delayed presentation of the primary tumor, more abundantly available energy sources within the peritoneum, and dysfunctional metabolic processes.

Appendix

Table 4 Univariable logistic regression analyses for the presence of synchronous peritoneal metastases

Variable	Synchronous PM n (%)	Univariable logistic regression analysis		
		OR	95% CI	p-value
Age (years)	293 (4.6)	0.999	0.987–1.10	0.819
Sex				0.750
Male	168 (4.5)	Ref	Ref	
Female	125 (4.7)	1.039	0.820–1.317	
Primary tumor location				< 0.001
Right colon	137 (6.9)	1.42	1.01–1.83	
Left colon	116 (5.0)	Ref	Ref	
Rectum	26 (1.3)	0.24	0.16–0.37	
Tumor differentiation				< 0.001
Good/moderate	124 (2.5)	Ref	Ref	
Poor/undifferentiated	49 (8.8)	3.703	2.627–5.128	
Tumor stage				< 0.001
T0–2	6 (0.3)	Ref	Ref	
T3	68 (2.2)	7.739	3.352–17.864	
T4	146 (16.0)	66.355	29.207–150,749	
Nodal stage				< 0.001
N0	55 (2.0)	Ref	Ref	
N1	75 (3.5)	1.816	1.277–2.584	
N2	120 (9.4)	5.134	3.704–7.116	
Tumor histology				< 0.001
Adenocarcinoma	224 (3.8)	Ref	Ref	
Mucinous adenocarcinoma	48 (9.6)	2.680	1.934–3.714	
Signet ring cell carcinoma	21 (29.2)	10.369	6.131–17.537	
Weight category				0.005
1. (BMI < 18.5); underweight	9 (7.4)	1.377	0.683–2.775	
2. (BMI 18.5–25); normal weight	135 (5.5)	Ref	Ref	
3. (BMI 25–30); overweight	108 (4.1)	0.733	0.565–0.950	
4. (BMI > 30); obesity	41 (3.3)	0.589	0.412–0.841	
Synchronous systemic metastasis				< 0.001
No	108 (2.0)	Ref	Ref	
Yes	185 (16.6)	9.638	7.526–12.344	

PM Peritoneal metastases, n Number, OR Odds ratio, CI Confidence interval, BMI Body mass index (in kg/m²)

Table 5 Univariable cox regression analyses for the development of metachronous peritoneal metastases after curative primary tumor resection

Variable	metachronous PM n (%)	Univariable Cox regression analysis		
		HR	95% CI	p-value
Age (years)	278 (5.1)	0.991	0.979–1.003	0.146
Sex				0.450
Male	156 (4.9)	Ref	Ref	
Female	122 (5.4)	1.096	0.864–1.388	
Primary tumor location				0.189
Right colon	107 (6.4)	1.286	0.981–1.685	
Left colon	106 (5.2)	Ref	Ref	
Rectum	65 (3.8)	1.155	0.846–1.576	
Tumor differentiation				< 0.001
Good/moderate	206 (4.7)	Ref	Ref	
Poor/undifferentiated	38 (8.7)	2.173	1.537–3.071	
Tumor stage				< 0.001
T0–2	20 (1.0)	Ref	Ref	
T3	152 (5.5)	5.852	3.674–9.328	
T4	106 (17.0)	18.822	11.672–30.354	
Nodal stage				< 0.001
N0	51 (2.0)	Ref	Ref	
N1	118 (6.5)	3.339	2.405–4.638	
N2	107 (11.0)	6.6412	4.593–8.952	
Tumor histology				< 0.001
Adenocarcinoma	233 (4.7)	Ref	Ref	
Mucinous adenocarcinoma	34 (8.2)	1.786	1.247–2.560	
Signet ring cell carcinoma	11 (24.4)	6.277	3.428–11.494	
Weight category				0.376
1. (BMI < 18.5); underweight	1 (1.1)	0.215	0.030–1.537	
2. (BMI 18.5–25); normal weight	107 (5.4)	Ref	Ref	
3. (BMI 25–30); overweight	117 (5.2)	0.913	0.703–1.187	
4. (BMI > 30); obesity	53 (4.8)	0.857	0.617–1.191	
Synchronous systemic metastasis				< 0.001
Yes	68 (15.9)	5.374	4.083–7.073	
No	210 (4.2)	Ref	Ref	

PM Peritoneal metastases, n Number, HR Hazard ratio, CI Confidence interval, BMI Body mass index (in kg/m²)

Abbreviations

BMI	Body mass index
CI	Confidence interval
CPM	Colorectal peritoneal metastases
CRC	Colorectal cancer
HR	Hazard ratio
ICD-O	International Classification of Disease–Oncology
NCR	Netherlands Cancer Registry
OR	Odds ratio
PCI	Peritoneal cancer index
PM	Peritoneal metastases
SD	Standard deviation
TNM	Tumor node metastasis

Acknowledgements

None.

Authors' contributions

Conceptualization, SN and IH; methodology, SN and FE; software, VV; validation, RL, SN and FE; formal analysis, VV; investigation, SN, VV, IH, and RL; resources, FE; data curation, RL, IH and VV; writing—original draft preparation, VV and SN; writing—review and editing, FE, RL, and IH; Visualization, RL and VV; supervision, SN; project administration, VV; funding acquisition, IH. All authors have read and agreed to the published version of the manuscript.

Authors' information

None.

Funding

No external funding was received for this manuscript.

Availability of data and materials

Data will be made available by corresponding author upon reasonable request.

Declarations**Ethics approval and consent to participate**

Due to the nationwide and anonymous nature of the data, no medical ethical approval was required for this study. The study was conducted in accordance with the Declaration of Helsinki and was approved by the scientific research board of the Netherlands Cancer Registry.

Consent for publication

Not applicable.

Competing interests

De Hingh reports an unrestricted research grant from RanD/QPS and Roche, outside the submitted work, paid to the institute.

Author details

¹Department of Surgery, Catharina Cancer Institute, Catharina Hospital, PO Box 1350, Eindhoven 5602 ZA, the Netherlands. ²Netherlands Comprehensive Cancer Organisation, Department of Research and Development, Utrecht, the Netherlands. ³GROW-School for Oncology and Development Biology, Maastricht University, Maastricht, the Netherlands.

Received: 11 April 2023 Accepted: 3 October 2023

Published online: 16 October 2023

References

- Organization WHW. Obesity and overweight. 2021. 31–10–2022.
- Nederland IK. Cijfers Darmkanker. 2022. 31–10–2022.
- Lurvink RJ, Bakkers C, Rijken A, van Erning FN, Nienhuijs SW, Burger JW, et al. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study. *Eur J Surg Oncol*. 2021;47(5):1026–33.
- Benson AB 3rd. Epidemiology, disease progression, and economic burden of colorectal cancer. *J Manag Care Pharm*. 2007;13(6 Suppl C):S5–18.
- Moayyedi P. The epidemiology of obesity and gastrointestinal and other diseases: an overview. *Dig Dis Sci*. 2008;53(9):2293–9.
- Lauby-Secretan B, Scocciati C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer—viewpoint of the IARC Working Group. *N Engl J Med*. 2016;375(8):794–8.
- Barone I, Giordano C, Bonfiglio D, Ando S, Catalano S. The weight of obesity in breast cancer progression and metastasis: Clinical and molecular perspectives. In *Seminars in cancer biology*. Academic Press. 2020;60:274–84.
- Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med*. 2011;17(11):1498–503.
- Annett S, Moore G, Robson T. Obesity and cancer metastasis: molecular and translational perspectives. *Cancers (Basel)*. 2020;12(12):3798.
- Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. *Gut*. 2013;62(6):933–47.
- Gerber SA, Rybalko VV, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. *Am J Pathol*. 2006;169(5):1739–52.
- Vecchié A, Dallegrì F, Carbone F, Bonaventura A, Liberale L, Portincasa P, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. *Eur J Intern Med*. 2018;48:6–17.
- Park JW, Chang SY, Lim JS, Park SJ, Park JJ, Cheon JH, et al. Impact of visceral fat on survival and metastasis of stage III colorectal cancer. *Gut Liver*. 2022;16(1):53–61.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

